Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK+ anaplastic large cell lymphoma

Leukemia Research

Volumn 38, Issue 4, 2014, Pages 503-508

  Hamedani, Farid Saei ^a   Cinar, Munevver ^a   Mo, Zhicheng ^a   Cervania, Melissa A ^a   Amin, Hesham M ^b,c   Alkan, Serhan ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

ALCL; Crizotinib; MCL 1; NPM ALK; STAT3

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CASPASE 3; CRIZOTINIB; NUCLEOPHOSMIN; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; FUSION GENE; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ALCL; CRIZOTINIB; MCL-1; NPM-ALK; STAT3;

APOPTOSIS; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; PYRIDINES; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84897113664     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.12.027     Document Type: Article

References (28)

1. Stein H., Mason D.Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985, 66:848-858.
2. Stein H., Foss H.D., Durkop H., Marafioti T., Delsol G., Pulford K., et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000, 96:3681-3695.
3. Piccaluga P.P., Gazzola A., Mannu C., Agostinelli C., Bacci F., Sabattini E., et al. Pathobiology of anaplastic large cell lymphoma. Adv Hematol 2010, 345053.
4. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
5. Duyster J., Bai R.Y., Morris S.W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001, 20:5623-5637.
6. Morris S.W., Naeve C., Mathew P., James P.L., Kirstein M.N., Cui X., et al. ALK, the chromosome 2 gene locus altered by the t(2; 5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997, 14:2175-2188.
7. Borer R.A., Lehner C.F., Eppenberger H.M., Nigg E.A. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989, 56:379-390.
8. Bischof D., Pulford K., Mason D.Y., Morris S.W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997, 17:2312-2325.
9. Zamo A., Chiarle R., Piva R., Howes J., Fan Y., Chilosi M., et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002, 21:1038-1047.
10. Amin H.M., McDonnell T.J., Ma Y., Lin Q., Fujio Y., Kunisada K., et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004, 23:5426-5434.
11. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., Raz R., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-629.
12. Falini B., Pileri S., Zinzani P.L., Carbone A., Zagonel V., Wolf-Peeters C., et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999, 93:2697-2706.
13. Gascoyne R.D., Aoun P., Wu D., Chhanabhai M., Skinnider B.F., Greiner T.C., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999, 93:3913-3921.
14. Pulford K., Lamant L., Espinos E., Jiang Q., Xue L., Turturro F., et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004, 61:2939-2953.
15. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
16. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67:4408-4417.
17. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
18. Wood G.S., Hardman D.L., Boni R., Dummer R., Kim Y.H., Smoller B.R., et al. Lack of the t(2; 5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood 1996, 88:1765-1770.
19. Lowe E.J., Sposto R., Perkins S.L., Gross T.G., Finlay J., Zwick D., et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer 2009, 52:335-339.
20. Woessmann W., Zimmermann M., Lenhard M., Burkhardt B., Rossig C., Kremens B., et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 2011, 29:3065-3071.
21. Kasprzycka M., Marzec M., Liu X., Zhang Q., Wasik M.A., Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T.regulatory cell phenotype by activating STAT3 Proc Natl Acad Sci USA 2006, 103:9964-9969.
22. Nasr M.R., Laver J.H., Chang M., Hutchison R.E. Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: a report from the children's oncology group. Am J Clin Pathol 2007, 127:770-778.
23. Khoury J.D., Medeiros L.J., Rassidakis G.Z., Yared M.A., Tsioli P., Leventaki V., et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003, 9:3692-3699.
24. Piva R., Pellegrino E., Mattioli M., Agnelli L., Lombardi L., Boccalatte F., et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006, 116:3171-3182.
25. Desjobert C., Renalier M.H., Bergalet J., Dejean E., Joseph N., Kruczynski A., et al. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood 2011, 117:6627-6637.
26. Rust R., Harms G., Blokzijl T., Boot M., Diepstra A., Kluiver J., et al. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma. J Clin Pathol 2005, 58:520-524.
27. Rassidakis G.Z., Sarris A.H., Herling M., Ford R.J., Cabanillas F., McDonnell T.J., et al. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol 2001, 159:527-535.
28. Rassidakis G.Z., Jones D., Lai R., Ramalingam P., Sarris A.H., McDonnell T.J., et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol 2003, 200:240-248.